annb0t
Top 20
The analysts covering Neuren Pharmaceuticals Limited (ASX:NEU) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business.
Following the latest downgrade, the current consensus, from the six analysts covering Neuren Pharmaceuticals, is for revenues of AU$66m in 2025, which would reflect a stressf...
>>> Read more: News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat
Following the latest downgrade, the current consensus, from the six analysts covering Neuren Pharmaceuticals, is for revenues of AU$66m in 2025, which would reflect a stressf...
>>> Read more: News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat
